1. Trần Mạnh Bình, Nguyễn uang Đạt, Hóa học hữu cơ tập 1-2, Nxb Y học, 2007, Hà Nội.
2. Nguyễn Hải Nam, Liên quan giữa cấu trúc và tác dụng sinh học, Tài liệu sau đại học, 2011, Nhà xuất bản y học.
3. Đào Thị Kim Oanh, Tổng hợp và thử hoạt tính sinh học của một số đãn chất acid hydroxamic hướng ức chế enzym histon deacetylase, Luận án tiến sĩ Dược học, Thư viện Đại học Dược Hà Nội, 2013, Hà Nội.
Tiếng Anh
4. Chittari P, Brian G, et al. Design and synthesis of aryl ether and sulfone hydroxamic acids as potent histone deacetylase (HDAC) inhibitors.
Bioorganic and Medicinal Chemistry, 2011; pp 324-328.
5. Christian A. G. N. Montalbettiand Virginie Falque. Amide bond formation and peptide coupling. Tetrahedron, 2005; 61: 10827-10852. 6. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC.
Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol, 2005; 45:495–528.
7. Glaser KB. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol, 2007; 74: 659-871.
8. Gray SG and Esktrom TJ. The human histone deacetylase family. Exp Cell Res, 2001; 262: 75-83.
9. Harish R, Avantika A, et al. 2,5-disubstituted-1,3,4- oxadiazole/thiadiazole hydroxamic acid as surface recognition moiety: Design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors.Bioorganic and Medicinal Chemistry, 2011, 21:
5735-5738.
10. Jessica E. Bolden, Melissa J. Peart and Ricky W. Johnstone. Anticancer activities of histone deacetylase inhibitors. Nature Publishing Group,
2006; 5: 769-784.
11. Jhih-Bin C, Ting-Rong C, et al. Design and Synthesis of Dual-Action Inhibitors Targeting Histone Deacetylases and 3-Hydroxy-3- methylglutaryl Coenzyme A Reductase for Cancer Treatment. J. Med. Chem., 2013, 56 (9), 3645–3655.
12. Johnstone RW. Histone-deacetylase inhibitor: novel drugs for the treatment of cancer. Nature Rev Drug Disc, 2002;1: 287-99.
13. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 1997; 46: 3-26.
14. Lu A, Luo H, Shi M, Wu G, Yuan Y, Liu J. Design, synthesis and docking studies on benzamide derivatives as histone deacetylase inhibitors.Bioorg Med Chem Lett 21, 2011, pp. 4924–7.
15. MA Glozak and E Seto. Histone deacetylase and cancer. Oncogene,
2006; 26: 5420-5432.
16. Marks PA, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nature Rev Cancer 2001; 1: 194-202. 17. Nam NH, Huong TL, Dung DTM, et al. Synthesis, bioevaluation and
docking study of 5-substitutedphenyl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents.
J Enzyme Inhib Med Chem,2013.
18. Peng Guan, eng’e Sun, et al. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors. Bioorganic and Medicinal
Chemistry 20, 2012, pp 3865-3872.
19. Rossi C, Porcelloni M, et al. Alkyl piperidine and alkyl piperazine hydroxamic acids as HDAC inhibitors. Bioorganic and Medicinal Chemistry, 2011, 21(8):2305-2308.
20. Ruijter de A.J el al. HDACs: Characterization of classical HDAC family
J. Biol. Chem, 2003; 370: 737-49.
21. Verdin E, Dequiedt F and Kasler HG. Class II histone deacetylase: versatile regulator. Trend Genet, 2003; 19: 286-293.
22. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: what are the cancer relevant targets? Cancer Lett, 2009; 277: 8-21.
23. Youngson Robert M.Collins Dictionary of Human Biology, HarperCollins,London, 2006. (adsbygoogle = window.adsbygoogle || []).push({});
Phụ lục 1. Phổ hồng ngoại (IR) chất Va
Ten may: GX-PerkinElmer-USA Nguoi do: Nguy en Thi Son DT: 0912140352